Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer - Drug Trials For Money - Paid Clinical Trials

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Condition:   Medullary Thyroid Cancer
Interventions:   Drug: Selpercatinib;   Drug: Cabozantinib;   Drug: Vandetanib
Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022 / by / in
Comments